(Total Views: 495)
Posted On: 09/30/2019 3:53:27 PM
Post# of 72447
Company buys a drug that no one wants for $5 million bucks, makes it successful in clinical trials, and gets a huge payday.
I'm not talking about IPIX -- yet. But for all those naysayers who claim this can't happen -- here's evidence that it can and does happen.
https://endpts.com/dova-pharmas-bet-on-eisai-...cquire-it/
I'm not talking about IPIX -- yet. But for all those naysayers who claim this can't happen -- here's evidence that it can and does happen.
https://endpts.com/dova-pharmas-bet-on-eisai-...cquire-it/
Quote:
Dova Pharmaceuticals paid Japan’s Eisai a paltry $5 million upfront for the rights to the Phase III-ready avatrombopag. The following year, the Durham, North Carolina-based company made its public debut with a $75 million IPO, and by 2018 the drug — branded as Doptelet — secured FDA approval. Dova’s bet paid off handsomely — on Monday, the company unveiled Swedish Orphan Biovitrum AB was acquiring its shares in a deal worth up to a robust $915 million.
(5)
(0)
